December 31, 2013
New 125I brachytherapy source IsoSeed I25.S17plus: Monte Carlo dosimetry simulation and comparison to sources of similar design
Purpose: To determine the relative dose rate distribution around the new 125I brachytherapy source IsoSeed I25.S17plus and report results in a form suitable for clinical use. Results for the new source are also compared to corresponding results for other commercially available 125I sources of similar design...
December 31, 2013
Time to failure after definitive therapy for prostate cancer: implications for importance of aggressive local treatment
Purpose: To explore patterns of time to failure in men receiving high doses of permanent seed brachytherapy with or without external beam radiation therapy as a function of risk status...
December 31, 2013
Prostate-specific antigen bounce predicts for a favorable prognosis following brachytherapy: a meta-analysis
Purpose: Controversy exists whether the prostate-specific antigen (PSA) bounce phenomenon following definitive radiation for prostate cancer has prognostic significance. Here, we perform a meta-analysis to determine the association between PSA bounce and biochemical control after brachytherapy alone...
December 24, 2013
The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma
PURPOSE: To present the American Brachytherapy Society (ABS) guidelines for plaque brachytherapy of choroidal melanoma and retinoblastoma...
November 01, 2013
Monotherapeutic high-dose-rate brachytherapy for prostate cancer: A dose reduction trial
Purpose: To report preliminary results of our second regimen with 45.5 Gy/7 fractions aiming to reduce toxicity, compared with our first regimen with 54 Gy/9 fractions, using high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer...
September 26, 2013
EGSnrc Monte Carlo-aided dosimetric studies of the new BEBIG 60Co HDR brachytherapy source
Purpose: The purpose of this study is to obtain the dosimetric parameters of the new BEBIG 60Co brachytherapy source following by TG-43U1 recommendation with appropriate electron cutoff energy (0.521 MeV)...
September 26, 2013
Vaginal cuff dehiscence after vaginal cuff brachytherapy for uterine cancer. A case report
Vaginal cuff dehiscence is a rare, but potentially serious complication after total hysterectomy. We report a case of vaginal cuff dehiscence after vaginal cuff brachytherapy. A 62 year old female underwent a robotic-assisted laparoscopic hysterectomy with bilateral salpingo-oophorectomy...
July 12, 2013
Biochemical outcomes for patients with intermediate risk prostate cancer treated with I-125 interstitial brachytherapy monotherapy
Background/purpose: Routine use of I-125 interstitial brachytherapy (BT) alone in intermediate risk (IR) prostate cancer is controversial. It is often combined with external beam radiotherapy (EBRT). The biochemical outcome of a large cohort of only IR disease treated with BT monotherapy is reported...
July 11, 2013
Quality of life impact of treatments for localized prostate cancer: Cohort study with a 5 year follow-up
Purpose: To assess long-term quality of life (QoL) impact of treatments in localized prostate cancer patients treated with radical prostatectomy, external beam radiotherapy or brachytherapy...
Read More
May 20, 2013
Trends in the Utilization of Brachytherapy in Cervical Cancer in the United States
Purpose: To determine the trends in brachytherapy use in cervical cancer in the United States and to identify factors and survival benefits associated with brachytherapy treatment...
March 29, 2013
Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer – between options
Purpose: Permanent low-dose-rate (LDR-BT) and temporary high-dose-rate (HDR-BT) brachytherapy are competitive techniques for clinically localized prostate radiotherapy. Although a randomized trial will likely never to be conducted comparing these two forms of brachytherapy...
Search in Cancer News
GEC-ESTRO Brachytherapy Guidelines:
ABS Brachytherapy Guidelines and Consensus Statements:
